Zura Bio Limited ZURA

ZURA Company Overview

Zura Bio Limited is a clinical-stage biotechnology company focused on developing novel immunology therapies for autoimmune and inflammatory diseases. The company operates within the biotechnology and biopharmaceutical industries, with a strategic emphasis on immune modulation and precision-targeted biologics. Zura Bio’s primary value drivers are its clinical development programs targeting immune pathways associated with chronic inflammatory disorders, particularly through dual-pathway inhibition approaches intended to improve efficacy and durability relative to existing therapies.

The company was formed in 2022 and became publicly traded on Nasdaq under the ticker ZURA following a business combination with a special purpose acquisition company in 2023. Zura Bio’s development strategy has centered on acquiring and advancing immunology assets with prior clinical or preclinical validation. Its positioning is based on targeting large global autoimmune disease markets where unmet medical need remains significant despite the presence of established biologic therapies.